Cogent Biosciences, a biotechnology firm, announced that Andrew Robbins, CEO, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. This virtual event will occur from February 14-18, 2022, with Robbins' chat streaming live on February 16 at 10:00 a.m. ET. A recording will be available for 90 days post-event. Cogent Biosciences focuses on precision therapies for genetically defined diseases, notably its drug bezuclastinib, targeting mutations associated with systemic mastocytosis and gastrointestinal stromal tumors.
On October 5, 2020, Unum Therapeutics Inc. announced its rebranding to Cogent Biosciences, Inc. (NASDAQ: COGT), effective October 6, 2020. The name change aligns with its focus on developing precision therapies for genetically defined diseases. Cogent provided an update on its lead asset, PLX9486, set to be presented at the upcoming CTOS Annual Meeting on November 20, highlighting a promising 11 months median progression-free survival in advanced GIST patients. The company has a strong cash position post-acquisition, ensuring operational stability into 2023.
Unum Therapeutics (Nasdaq: UMRX) announced the sale of its BOXR cell-based therapy programs to SOTIO for an upfront payment of $8.1 million. This agreement allows SOTIO to advance the development of Unum's lead candidate, BOXR1030, with potential additional milestones of up to $3.4 million. The sale, effective August 28, 2020, enables Unum to focus on precision kinase inhibitors, particularly PLX9486, while retaining certain technologies. Following this strategic shift, Unum appointed Peter Harwin as Board Chair to guide future developments.
Unum Therapeutics Inc. (Nasdaq: UMRX) reported its Q2 2020 financial results, highlighting collaboration revenue of $0.5 million, a drop from $3.1 million year-over-year. R&D expenses decreased to $5.1 million, down from $10.6 million in Q2 2019, while G&A expenses also fell to $2.8 million. Net loss narrowed to $7.4 million, or $0.24 per share, compared to $10.5 million, or $0.34 per share, in the prior year. The acquisition of Kiq LLC and a private placement raised $104.4 million, enhancing the company's pipeline for precision kinase inhibitors, particularly PLX9486 for cancer treatments.